Nothing Special   »   [go: up one dir, main page]

WO1999047678A3 - Interferon alpha plasmids and delivery systems, and methods of making and using the same - Google Patents

Interferon alpha plasmids and delivery systems, and methods of making and using the same Download PDF

Info

Publication number
WO1999047678A3
WO1999047678A3 PCT/US1999/005394 US9905394W WO9947678A3 WO 1999047678 A3 WO1999047678 A3 WO 1999047678A3 US 9905394 W US9905394 W US 9905394W WO 9947678 A3 WO9947678 A3 WO 9947678A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
constructs
interferon alpha
delivery
making
Prior art date
Application number
PCT/US1999/005394
Other languages
French (fr)
Other versions
WO1999047678A2 (en
WO1999047678A9 (en
Inventor
Jeff Nordstrom
Federica Pericle
Allain Rolland
Robert Ralston
Original Assignee
Valentis Inc
Jeff Nordstrom
Federica Pericle
Allain Rolland
Robert Ralston
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valentis Inc, Jeff Nordstrom, Federica Pericle, Allain Rolland, Robert Ralston filed Critical Valentis Inc
Priority to EP99911340A priority Critical patent/EP1064383A2/en
Priority to CA002323604A priority patent/CA2323604A1/en
Priority to JP2000536861A priority patent/JP2002506647A/en
Priority to AU30003/99A priority patent/AU3000399A/en
Publication of WO1999047678A2 publication Critical patent/WO1999047678A2/en
Publication of WO1999047678A3 publication Critical patent/WO1999047678A3/en
Publication of WO1999047678A9 publication Critical patent/WO1999047678A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The present invention relates to gene delivery and gene therapy, and provides novel nucleic acid constructs for expression of interferon alpha in a mammal, formulations for delivery that incorporate a nucleic acid construct for expression, and methods for preparing and using such constructs and formulations. In particular, this invention relates to plasmid constructs for delivery of therapeutic interferon alpha encoding nucleic acids to cells in order to modulate tumor activity, methods of using those constructs (including combination therapy with other agents, such as cytokines, preferably IL-12), as well as methods for preparing such constructs.
PCT/US1999/005394 1998-03-19 1999-03-12 Interferon alpha plasmids and delivery systems, and methods of making and using the same WO1999047678A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP99911340A EP1064383A2 (en) 1998-03-19 1999-03-12 Interferon alpha plasmids and delivery systems, and methods of making and using the same
CA002323604A CA2323604A1 (en) 1998-03-19 1999-03-12 Interferon alpha plasmids and delivery systems, and methods of making and using the same
JP2000536861A JP2002506647A (en) 1998-03-19 1999-03-12 Interferon alpha plasmid and delivery system, and methods of making and using the same
AU30003/99A AU3000399A (en) 1998-03-19 1999-03-12 Interferon alpha plasmids and delivery systems, and methods of making and using the same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7865498P 1998-03-19 1998-03-19
US60/078,654 1998-03-19

Publications (3)

Publication Number Publication Date
WO1999047678A2 WO1999047678A2 (en) 1999-09-23
WO1999047678A3 true WO1999047678A3 (en) 1999-12-09
WO1999047678A9 WO1999047678A9 (en) 2000-11-09

Family

ID=22145430

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/005394 WO1999047678A2 (en) 1998-03-19 1999-03-12 Interferon alpha plasmids and delivery systems, and methods of making and using the same

Country Status (5)

Country Link
EP (1) EP1064383A2 (en)
JP (1) JP2002506647A (en)
AU (1) AU3000399A (en)
CA (1) CA2323604A1 (en)
WO (1) WO1999047678A2 (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001079289A2 (en) * 2000-04-14 2001-10-25 Zymogenetics, Inc. Human interferon, zinf2
US7632983B2 (en) 2000-07-31 2009-12-15 Biolex Therapeutics, Inc. Expression of monoclonal antibodies in duckweed
PT1305437E (en) 2000-07-31 2010-11-12 Biolex Therapeutics Inc Expression of biologically active polypeptides in duckweed
US8022270B2 (en) 2000-07-31 2011-09-20 Biolex Therapeutics, Inc. Expression of biologically active polypeptides in duckweed
EP1195436A1 (en) * 2000-10-04 2002-04-10 BOEHRINGER INGELHEIM INTERNATIONAL GmbH Expression vectors with modified ColE1 origin of replication for control of plasmid copy number
US7468242B2 (en) 2001-11-05 2008-12-23 Medgenics, Inc. Dermal micro organs, methods and apparatuses for producing and using the same
US8501396B2 (en) 2001-11-05 2013-08-06 Medgenics Medical Israel Ltd. Dermal micro-organs, methods and apparatuses for producing and using the same
EP2377403A1 (en) 2003-05-01 2011-10-19 Medgenics, Inc. A genetically modified dermal micro-organ expressing factor VIII
US7833754B2 (en) 2006-01-13 2010-11-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services IL-12 for expression in mammalian cell
WO2008033375A2 (en) 2006-09-14 2008-03-20 Medgenics Ltd. Long lasting drug formulations
US8454948B2 (en) 2006-09-14 2013-06-04 Medgenics Medical Israel Ltd. Long lasting drug formulations
WO2009140206A1 (en) * 2008-05-11 2009-11-19 The Gov. Of The U. S. A., As Represented By The Secretary Of The Dept. Of Health And Human Services Improved expression of il-12 family heterodimers
CN103260649A (en) 2010-06-15 2013-08-21 迈德詹尼克斯医疗以色列有限公司 Long lasting drug formulations
US9272024B2 (en) * 2011-12-12 2016-03-01 The Trustees Of The University Of Pennsylvania Compositions, comprising improved IL-12 genetic constructs and vaccines, immunotherapeutics and methods of using the same
JP7264867B2 (en) * 2017-03-31 2023-04-25 アッカニス・バイオテック・エフ・アンド・イー・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング・ウント・コムパニー・コマンディットゲゼルシャフト Prevention and treatment of non-melanoma skin cancer (NMSC)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996017063A1 (en) * 1994-11-28 1996-06-06 Vical Incorporated Plasmids suitable for il-2 expression
WO1996021470A2 (en) * 1995-01-13 1996-07-18 Genemedicine, Inc. Compositions of nucleic acid and viscosity-increasing polymers for use in gene therapy
WO1997000085A1 (en) * 1995-06-19 1997-01-03 University Of Medicine & Dentistry Of New Jersey Gene therapy of solid tumors with interferons alone or with other immuno-effector proteins
WO1997000321A1 (en) * 1995-06-14 1997-01-03 Commonwealth Scientific And Industrial Research Organisation Immune response modulators and uses therefor
WO1997033998A1 (en) * 1996-03-14 1997-09-18 The Immune Response Corporation Targeted delivery of genes encoding interferon
WO1998017689A2 (en) * 1996-10-18 1998-04-30 Valentis Inc. Il-12 gene expression and delivery systems and uses
WO1998034952A2 (en) * 1997-02-10 1998-08-13 Valentis, Inc. Il-2 gene expression and delivery systems and uses

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996017063A1 (en) * 1994-11-28 1996-06-06 Vical Incorporated Plasmids suitable for il-2 expression
WO1996021470A2 (en) * 1995-01-13 1996-07-18 Genemedicine, Inc. Compositions of nucleic acid and viscosity-increasing polymers for use in gene therapy
WO1997000321A1 (en) * 1995-06-14 1997-01-03 Commonwealth Scientific And Industrial Research Organisation Immune response modulators and uses therefor
WO1997000085A1 (en) * 1995-06-19 1997-01-03 University Of Medicine & Dentistry Of New Jersey Gene therapy of solid tumors with interferons alone or with other immuno-effector proteins
WO1997033998A1 (en) * 1996-03-14 1997-09-18 The Immune Response Corporation Targeted delivery of genes encoding interferon
WO1998017689A2 (en) * 1996-10-18 1998-04-30 Valentis Inc. Il-12 gene expression and delivery systems and uses
WO1998034952A2 (en) * 1997-02-10 1998-08-13 Valentis, Inc. Il-2 gene expression and delivery systems and uses

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
BELLDEGRUN A ET AL: "HUMAN RENAL CARCINOMA LINE TRANSFECTED WITH INTERLEUKIN-2 AND/OR INTERFERON ALPHA GENE(S): IMPLICATIONS FOR LIVE CANCER VACCINES", JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 85, no. 3, 3 February 1993 (1993-02-03), pages 207 - 216, XP002057839, ISSN: 0027-8874 *
FERRANTINI M ET AL: "ALPHA1-INTERFERON GENE TRANSFER INTO METASTATIC FRIEND LEUKEMIA CELLS ABROGATED TUMORIGENICITY IN IMMUNOCOMPETENT MICE: ANTITUMOR THERAPY BY MEANS OF INTERFERON-PRODUCING CELLS", CANCER RESEARCH, vol. 53, 1 March 1993 (1993-03-01), pages 1107 - 1112, XP002015124, ISSN: 0008-5472 *
GAO X ET AL: "CATIONIC LIPOSOME-MEDIATED GENE TRANSFER", GENE THERAPY, vol. 2, no. 10, 1 December 1995 (1995-12-01), pages 710 - 722, XP000749400, ISSN: 0969-7128 *
H. ALILA ET AL: "Expression of biologically active human Insulin-like growth factor-I following intramuscular injection of a formulated plasmid in rats", HUMAN GENE THERAPY, vol. 8, no. 15, 10 October 1997 (1997-10-10), pages 1785 - 1795, XP002118452 *
M. COLEMAN ET AL: "Nonviral Interferon alpha Gene therapy inhibits growth of established tumors by eliciting a systemic immune response", HUMAN GENE THERAPY, vol. 9, 10 October 1998 (1998-10-10), pages 2223 - 2230, XP002118169 *
M. FERRANTINI ET AL: "IFN-alpha1 gene expression into a metastatic murine adenocarcinoma (TS/A) results in CD8+ T cell-mediated tumor rejection and development of antitumor immunity", JOURNAL OF IMMUNOLOGY, vol. 153, 1994, pages 4604 - 4615, XP002118168 *
R.J. MUMPER ET AL: "protective interactive noncondensing (PINC) polymers for enhanced plasmid distribution and expression in rat skeletal muscle", JOURNAL OF CONTROLLED RELEASE, vol. 52, 2 March 1998 (1998-03-02), pages 191 - 203, XP004113667 *
RUSSELL J. MUMPER ET AL: "Polyvinyl derivatives as novel interactive polymers for controlled Gene delivery to muscle", PHARMACEUTICAL RESEARCH, vol. 13, no. 5, May 1996 (1996-05-01), pages 701 - 709, XP002118167 *
SK MENDIRATTA ET AL: "Intratumoral delivery of iL-12 gene by polyvinyl polymeric vector system to murine renal and colon carcinoma results in potent antitumor immunity", GENE THERAPY, vol. 6, no. 5, May 1999 (1999-05-01), pages 83 - 839, XP002118170 *

Also Published As

Publication number Publication date
JP2002506647A (en) 2002-03-05
AU3000399A (en) 1999-10-11
WO1999047678A2 (en) 1999-09-23
WO1999047678A9 (en) 2000-11-09
EP1064383A2 (en) 2001-01-03
CA2323604A1 (en) 1999-09-23

Similar Documents

Publication Publication Date Title
WO1999047678A3 (en) Interferon alpha plasmids and delivery systems, and methods of making and using the same
AU5788096A (en) Plasmid for delivery of nucleic acids to cells and methods of use
AU2790292A (en) Viral recombinant vectors for expression in muscle cells
AU568067B2 (en) Oligonucleotide therapeutic agent and methods of making same
EP0042246A2 (en) Plasmid
CA2182303A1 (en) Method of preparing a viral vector by homologous intermolecular recombination
AU3246300A (en) Polypeptides having galactose oxidase activity and nucleic acids encoding same
MY134810A (en) Targeted gene expression of thrombopoietein, dnase i and b-interferon
WO1998034952A3 (en) Il-2 gene expression and delivery systems and uses
WO2000006759A3 (en) Anti-angiogenesis plasmids and delivery systems, and methods of making and using the same
CA2091346A1 (en) Methods and compositions for genetic therapy and potentiation of anti-tumor immunity
AU2077197A (en) Polypeptides having phytase activity and nucleic acids encoding same
WO1999046366A8 (en) Uses for humane non-autologous mesenchymal stem cells
WO1998046781A3 (en) Novel transgene expression system for increased persistence
WO2003023000A3 (en) Linear dna fragments for gene expression
AU682140B2 (en) Multidrug resistance gene
WO2000073478A3 (en) Recombinant adenoviral vectors expressing chimeric fiber proteins for cell specific infection and genome integration
NZ505063A (en) Pharmaceutical use of long pentraxin PTX3 in treating tumour conditions
EP0111814A3 (en) The cloning and expression of nucleotide sequences encoding bovine growth hormone
WO1996003506A3 (en) Analog of haemophilus hin47 with reduced protease activity
AUPN154295A0 (en) Nucleic acid molecule encoding a protein with avian gamma-interferon activity
EP1007717B8 (en) Methods and compositions for cancer therapies using genes encoding interferon-beta
WO2000008157A3 (en) Human anion transporter genes atnov
AUPM772494A0 (en) Improvements in production of proteins in host cells
EP0276778A3 (en) High level expression in e. coli of soluble mature hil-1beta and derivatives with altered biological activity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 30003/99

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2323604

Country of ref document: CA

Ref country code: CA

Ref document number: 2323604

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 536861

Kind code of ref document: A

Format of ref document f/p: F

NENP Non-entry into the national phase

Ref country code: KR

WWE Wipo information: entry into national phase

Ref document number: 1999911340

Country of ref document: EP

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/16-16/16, DRAWINGS, REPLACED BY NEW PAGES 1/19-19/19; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWP Wipo information: published in national office

Ref document number: 1999911340

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 1999911340

Country of ref document: EP